The pharmaceutical industry is in the midst of a steady period of moderate growth, but financial pressure will build toward the middle part of the decade as many key blockbuster brands face loss of exclusivity (LOE). The window for launching new growth drivers to fill the expected revenue gap is narrowing.
The Next Big Patent Cliff Is Coming, And Time Is Running Out To Pad The Fall
Blockbusters like Stelara, Eliquis, Prolia and Ibrance are poised to lose US exclusivity over the next five years; pressure is mounting for industry to replenish the portfolio with the next high-growth brands.
More from Strategy
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
• By
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.